Project Grant R01CA311423
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Fred Hutchinson Cancer Center a Project Grant totaling $139,184 under the Cancer Research Manpower program (CFDA 93.398) for the period of July 1, 2025, through June 30, 2027. This award funds research investigating the role of RNA components of the translation apparatus in prostate cancer plasticity and therapy response. The project focuses on elucidating how prostate cancer leverages transfer RNA (tRNA) and 5'...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Fred Hutchinson Cancer Center $169,776 under the Cancer Research Manpower program (CFDA 93.398) for a two-year project (August 1, 2025–July 31, 2027) titled "Unraveling Myeloid-Mediated Mechanisms of Immunotherapy Resistance in Prostate Cancer Bone Metastases at Single-Cell Resolution." This project grant funds biomedical research training and investigator-initiated research focused on identifying and...
- Federal Project Grant Award Summary The National Cancer Institute awarded Fred Hutchinson Cancer Center a Project Grant totaling $737,945 under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop quantitative measurement tools for assessing determinants of evidence-based cancer care interventions. The project, which commenced May 4, 2026 and concludes April 30, 2029, will deliver flexible, tailorable item banks—collections of validated survey instruments—designed to measure...
- Federal Project Grant Award Summary The National Cancer Institute awarded The Johns Hopkins University a $354,658 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective August 1, 2025 through July 31, 2030. This award supports fundamental research investigating subclonal P27 (CDKN1B) loss as a driver of aggressive prostate cancer, with particular focus on understanding health disparities affecting Black or African American males who experience prostate cancer mortality...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Fred Hutchinson Cancer Center a Project Grant of $714,192 under the Cancer Detection and Diagnosis Research program (CFDA 93.394) effective June 1, 2026, through May 31, 2031. This award funds the development and validation of a novel lung cancer subtype-specific risk stratification approach designed to overcome critical limitations in current low-dose computed tomography (CT) screening protocols. The project will...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Fred Hutchinson Cancer Center a $716,319 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 11, 2026, with a completion date of May 31, 2031. This award supports research to optimize CD45-targeted Astatine-211 radioimmunotherapy for treating malignant and non-malignant blood disorders. The project builds on institutional expertise with the murine monoclonal antibody BC8, advancing from earlier...
- Federal Grant Award Summary Fred Hutchinson Cancer Center received a $712,569 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded on May 4, 2026, with a completion date of April 30, 2031. The grant supports research investigating the impact of KEAP1/NRF2 pathway activation on therapy response in lung neuroendocrine cancers, specifically small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). The research...
- Federal Project Grant Award Summary Fred Hutchinson Cancer Center received a $692,368 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) to support a five-year research initiative from June 1, 2026, through May 31, 2031. The project, titled "The MYC Transcription Factor Network: Elucidating Oncogenic and Tumor Suppressive Pathways," focuses on understanding how dysregulation of the MYC (Myc) transcription factor network...
- Federal Project Grant Award Summary Fred Hutchinson Cancer Center received a $439,639 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) awarded June 1, 2026, with a completion date of May 31, 2031. The award supports the development of methodological tools and guidance for microsimulation model calibration—a critical process for ensuring that computational models used to project the long-term effectiveness, harms, and...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Trustees of Columbia University in the City of New York a Project Grant of $531,825 under the Cancer Biology Research program (CFDA 93.396) effective August 1, 2025, with completion targeted for July 31, 2030. This research initiative focuses on understanding the molecular mechanisms of castration sensitivity in prostate epithelium, with the ultimate goal of improving therapeutic responses to androgen-deprivation therapy...
The National Cancer Institute (NCI) awarded Fred Hutchinson Cancer Center a $723,547 Project Grant under the Cancer Biology Research program (CFDA 93.396) on June 9, 2026, with a completion date of May 31, 2031. This five-year research initiative investigates the role of 5' untranslated regions (5' UTRs) in prostate cancer clonality and heterogeneity. The project delivers fundamental research on how distinct 5' UTR regions modulate protein synthesis and control clonal growth dynamics in prostate cancer through CRISPR screening, nucleotide-level characterization, and validation studies. Key research products include identification of novel gene regulatory mechanisms governing protein abundance independent of messenger RNA (mRNA) levels, determination of how 5' UTR elements influence clonal growth across different prostate cancer subtypes, and elucidation of how these regulatory elements respond to therapeutic interventions. This Cancer Biology Research award supports translational investigations expected to advance understanding of cancer development mechanisms with potential applications for improved prevention, detection, and treatment strategies for prostate cancer. The research conducted at Fred Hutchinson Cancer Center in Seattle, Washington will contribute fundamental knowledge to address prostate cancer's significant public health burden as the second leading cause of cancer-related deaths in men in the United States, with particular emphasis on understanding the genetic and molecular drivers of tumor heterogeneity.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $723.5k | 6/9/26 |